Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy

Jennifer A. Slyker,1 Corey Casper,1,2,3,4 Kenneth Tapia,1,5 Barbra Richardson,2 Lisa Bunts,4 Meei-Li Huang,6 Dalton Wamalwa,6 Sarah Benki-Nugent,4 and Grace John-Stewart1,2,3,7

Departments of 1Global Health, 2Epidemiology, and 3Medicine, Division of Allergy and Infectious Diseases, University of Washington, 4Divisions of Vaccine and Infectious Disease, Public Health Sciences, and Clinical Research, Fred Hutchinson Cancer Research Center, 5Department of Biostatistics, University of Washington, Seattle, 6Department of Pediatrics and Child Health, School of Medicine, University of Nairobi, Kenya, and Departments of 7Pediatrics and 8Laboratory Medicine, University of Washington, Seattle

We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus–infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.

Keywords. Epstein-Barr virus; primary infection; HIV; infant; antiretroviral therapy.

Epstein-Barr virus (EBV) is associated with several human immunodeficiency virus (HIV)–associated malignancies [1]. Risk factors for EBV-associated lymphomas include B-cell activation, unsuppressed HIV type 1 (HIV-1), low CD4 count, and starting antiretroviral therapy (ART) late [2–7]. ART initiation prior to EBV acquisition may have the potential to influence later development of EBV-associated malignancy via delayed infection, better EBV suppression, or limiting the latent EBV reservoir.

An increasing body of evidence suggests that HIV-1 protease inhibitors have broad off-target effects, including inhibition of γ-herpesvirus replication and antitumor activity [8, 9]. We compared rates of primary EBV infection and suppression between infants initiating ART regimens containing nevirapine (NVP) vs ritonavir-boosted lopinavir (LPV/r).

MATERIALS AND METHODS

Study Design and Cohort

The study was approved by the Institutional Review Board of the University of Washington and the Ethics and Research Committee of the University of Nairobi. This is a retrospective analysis of specimens collected during a randomized clinical trial with a 2-year prerandomization phase (NCT00428116 [10]); this report includes only the prerandomization period. Enrollment criteria were age <5 months, residence in Nairobi, no prior ART (other than for prevention of mother-to-child HIV transmission), retention in the study beyond ART initiation, and baseline specimen availability. ART was initiated shortly after enrollment; children with prior NVP exposure were initiated on an LPV/r-based regimen, and all others started NVP. Infants were assessed monthly, with quarterly blood collection [10]. We excluded 14 infants who initiated NVP-based regimens despite prior NVP exposure, whose specimens were reserved for ART resistance studies.

EBV Diagnostics

EBV DNA levels were measured from cryopreserved plasma until 24 months after ART initiation [11]. The lower limit of detection was 50 copies/mL. Infants with no EBV DNA detection received serologic testing of their final specimen collected at >6 months of age to determine infection status using enzyme-linked immunosorbent assay as previously described [11].

Statistical Analysis

Stata SE version 11.2 for Macintosh (StataCorp, College Station, Texas) was used for analysis. All tests were 2-tailed with α = .05. Characteristics were compared between groups using either the χ² test for categorical variables, or the Mann-Whitney U test for continuous variables.

Time to EBV infection and suppression were estimated using Kaplan-Meier survival analysis, and the log-rank test was used
to compare survival probabilities. Infection time was estimated as the age EBV was first detectable. Infants were considered to be at risk for EBV infection once they began ART; we thereby excluded infants who exited or died before starting ART or had EBV infection at enrollment. For EBV-infected infants, suppression was defined as the first time point at which an infant became EBV DNA undetectable for 2 consecutive visits. For all time-to-event analyses, infants not experiencing the event of interest were censored at death or last study visit.

Generalized estimating equations with a binomial link function and robust standard errors were used to estimate odds ratios (ORs) for EBV suppression. All models include time since EBV infection. For both unadjusted and adjusted models, ART regimen is time-updated.

RESULTS

Cohort Characteristics
Among the 100 infants enrolled in the trial, 64 met criteria for inclusion in the EBV study (Supplementary Figure 1). Characteristics of the infants and their caregivers are provided in Supplementary Table 1. Median age at enrollment was 3.6 months (interquartile range [IQR], 3.0–4.0), and infants were followed for a median of 24 months (IQR, 3.8–24). Mean infant CD4 percentage was low at enrollment (20% [SD, 8.3%]). ART was started at a median age of 4.1 months (IQR, 3.3–4.6), with 34 (53%) initiating LPV/r and 30 (47%) initiating NVP. All baseline infant and caregiver characteristics were similar between infants receiving LPV/r- and NVP-based regimens.

EBV Acquisition
A total of 18 infants were persistently EBV DNA negative throughout follow-up; 5 of these had specimens collected after 6 months of age, and 3 of these 5 were positive for EBV antibodies. Nine prevalent EBV infections were detected at enrollment (9/64 [14%]), prior to ART initiation; these infants had been enrolled at approximately 3 (n = 3) and 4 (n = 6) months of age. Overall, 77% of the infants we tested had evidence of EBV infection (49/64) and 72% had detectable EBV DNA (46/64).

The mean age at EBV infection was 8.8 months (95% confidence interval [CI], 6.6–11) overall; 7.8 months (95% CI, 5.0–11) in the LPV/r group, and 8.9 months (95% CI, 5.7–12) in the NVP group (P = .6; Figure 1A). The overall probability of EBV infection in ART-treated infants at 12 and 24 months was 0.65 (95% CI, .51–.79) and 0.93 (95% CI, .83–.98), respectively, and was similar between the LPV/r and NVP groups (data not shown).

EBV Viral Levels and Suppression
Overall, the median peak EBV load among infants with detectable EBV viremia was 2.5 log_{10} EBV DNA copies/mL (IQR, 2.0–2.9). Peak EBV DNA levels were similar between treatment groups (P = .7; Figure 1B).

Among the 46 EBV-infected infants with detectable EBV DNA, 27 (59%) later became undetectable for EBV DNA, at a mean time of 11 months (95% CI, 7.7–14; Figure 1C). Mean time to suppression was shorter in the LPV/r group (6.4 months [95% CI, 4.7–8.0]) compared with the NVP group (15 months [95% CI, 10–20]; log-rank P = .02).

Infants were grouped into 3 different patterns of EBV suppression; “good controllers” were EBV seropositive with no detection of EBV DNA, or had a single episode of EBV DNA detection followed by complete suppression, “poor controllers” had transient or persistent viremia lasting >3 months, and “unclassifiable” had EBV DNA detected only at their final study visit. The proportion of good controllers (54% in LPV/r vs 26% in NVP), poor controllers (35% in LPV/r vs 61% in NVP), and unclassifiable infants (12% in LPV/r vs 13% in NVP) differed significantly between the LPV/r and NVP groups (P = .03).

LPV/r, HIV-1 Viral Suppression, and CD4 Percentage
HIV-1 suppression <1000 copies/mL (OR, 4.9 [95% CI, 2.6–9.3]; P < .001), CD4 >25% (OR, 4.0 [95% CI, 1.8–8.8]; P < .001), and LPV/r use (OR, 3.1 [95% CI, 1.4–7.0]; P = .006) were associated with the odds of concurrent EBV suppression. LPV/r regimen remained significantly associated with EBV suppression when adjusting for HIV-1 suppression (OR = 3.1 [95% CI, 1.4–6.9]; P = .006) and retained a trend when adjusting for CD4 >25% (OR = 2.5 [95% CI, .91–6.8]; P = .07).

DISCUSSION

Our findings suggest that LPV/r-based ART may substantially accelerate EBV suppression compared with NVP-based regimens. As poor suppression of EBV infection is associated with EBV-related malignancies, our data suggest that initiation of LPV/r ART prior to infant EBV acquisition could potentially have implications for later risk of EBV-associated malignancy.

The probability of infant EBV infection, time to EBV acquisition, and peak EBV load reported here were similar to those observed in a cohort of treatment-naive children from the same clinic [11]. Together, these data suggest that early infant ART does not afford significant protection from EBV acquisition or limit peak systemic viral load. However, ART-treated children had a shorter time to EBV suppression (11 months) compared with untreated infants (17 months) in the earlier study [11]. Importantly, infants initiating LPV/r regimens suppressed virus approximately 8 months earlier than infants receiving NVP regimens and were more likely to be good EBV controllers. The association between LPV/r regimen and accelerated
EBV suppression does not appear to be mediated through better HIV-1 treatment responses in the LPV/r group; LPV/r was not associated with improved rates of HIV-1 suppression or CD4 reconstitution in the cohort (Benki-Nugent et al., manuscript in preparation), and the association between LPV/r and EBV suppression was independent of HIV-1 suppression. To our knowledge, the effect of LPV/r on EBV replication has not been studied, but several mechanisms could explain our observations, including better restoration of global lymphocyte function, a direct effect on EBV replication, or altered host B-cell cycling. Because there was no difference in EBV load between groups, a direct effect of LPV/r on EBV replication seems unlikely. Dewan and colleagues previously demonstrated that ritonavir inhibited EBV-immortalized lymphoblastoid cell line
(LCL) growth in vitro, and reduced LCL infiltration and growth in a mouse model by targeting NF-κB to induce cell cycle arrest and apoptosis [12], suggesting a potential effect of ritonavir on B cells undergoing lytic EBV replication.

Limitations of our study include its retrospective and observational design, lack of maternal EBV data, and short follow-up period. Our time-dependent analyses are limited by the high early mortality in the cohort, as many infants died before acquiring EBV or achieving suppression. Based on a small number of previous publications with longitudinal serology, we used 6 months of age to discriminate infant from maternal antibodies [13, 14]; although we are unable to completely rule out maternal antibodies, we would expect misclassification of outcome to be nondifferential with regards to ART exposure, and would therefore have the overall effect of understimating differences between study groups. Selection of first-line ART regimen was based upon prior infant NVP exposure; whether prior NVP exposure, or some other unidentified confounder, would affect EBV suppression is unknown.

In conclusion, ART did not protect HIV-infected infants from EBV acquisition or limit peak viremia. However, LPV/r-ART was associated with accelerated suppression of primary EBV infection. It will be important to determine the mechanism underlying the association between LPV/r and improved EBV control. As many African countries are currently adapting their guidelines to enable earlier infant diagnosis and ART, strategic implementation of particular ART regimens could have population-level implications for EBV-associated malignancies.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We acknowledge the contributions of the research personnel, laboratory staff, and the data management teams in Nairobi and Seattle. We are grateful to the Nairobi City Council Clinics for their participation and to the Departments of Pediatrics and Medical Microbiology at Kenyatta National Hospital for providing laboratory facilities. We are grateful to the OPH Study Team, including Judith Adhiambio, Daisy Chebet, and Drs Agnes Langat, Evelyn Ngugi, and Sasi Jonnalagadda. We thank Sandy Emery and Dr Julie Overbaugh (Fred Hutchinson Cancer Research Center) and Dr Bhavna Chohan (University of Nairobi) for assistance with transport and storage of specimens, measurement of HIV-1 loads, and provision of laboratory facilities. We thank Stacy Selke and Robert Bruneau (University of Washington [UW]) for technical support with specimen inventories, tracking, processing, and reporting, and Anne Cent (UW Virology Laboratory, Research Testing Service) for conducting the serologic assays. We are grateful to the UW Global Center for Integrated Health of Women, Children and Adolescents (Global WACh) Kizazi Working Group for reading and providing comments on the development of this study. Most of all, we thank the women and children who provided specimens and data to support this research.

Author contributions. J. A. S., B. R., and G. J.-S. conceived and acquired funding for the study. G. J.-S., D. W., and S. B.-N. developed the primary cohort, designed clinical protocols, collected the clinical data, and assisted with interpretation of clinical results. L. B. and M.-L. H. developed and executed the Epstein Barr Virus protocols and provided interpretation of results. J. A. S., C. C., K. T., and B. R. participated in design of the analyses and analyzed the data. The final manuscript was written by J. A. S., C. C., and G. J.-S. J. A. S had full access to all the data and takes responsibility for the integrity of the data, the accuracy of the data analysis, and the final responsibility for the decision to submit for publication.

Disclaimer. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. The funding sources were not involved in the analyses or interpretation of data. None of the authors was paid to write this article by a pharmaceutical company or other agency.

Financial support. This was supported by an HIV-Associated Malignancy Award (PI, J. A. S.) through a Center for AIDS Research (CFAR) award to the Fred Hutchinson Cancer Research Center (grant number P30 CA 015704–3553; PI, L. Corey) from the National Cancer Institute. Accrual of the study cohort was made possible though grant number HD-23412 from the US National Institutes of Child Health and Human Development and support to G. J.-S. via K24HD054314. J. A. S. is supported by K01AI087369 from the National Institute of Allergy and Infectious Diseases. This publication was also supported in part by the University of Washington CFAR (P30 AI027757).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


1336 • CID 2014:58 (1 May) • HIV/AIDS